Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year Low – Should You Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price hit a new 52-week low during trading on Monday . The company traded as low as $15.63 and last traded at $15.71, with a volume of 168337 shares traded. The stock had previously closed at $16.21.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KLRA. William Blair initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating for the company. Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $48.00 price target on the stock. Evercore started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating for the company. Weiss Ratings started coverage on Kailera Therapeutics in a report on Friday, August 14th. They set a “sell (d)” rating on the stock. Finally, Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.75.

Kailera Therapeutics Price Performance

The stock has a market capitalization of $2.02 billion and a PE ratio of -0.00. The business has a fifty day moving average price of $19.09.

Kailera Therapeutics (NASDAQ:KLRA) last issued its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, equities research analysts expect that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Trading of Kailera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System acquired a new stake in shares of Kailera Therapeutics during the second quarter worth $309,000. Frazier Life Sciences Management L.P. acquired a new position in Kailera Therapeutics in the second quarter valued at about $24,233,000. Atlas Venture Life Science Advisors LLC acquired a new position in Kailera Therapeutics in the second quarter valued at about $113,923,000. Finally, Wellington Management Group LLP bought a new position in Kailera Therapeutics during the second quarter worth about $64,308,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.